Samarth Kulkarni - 18 Feb 2024 Form 4 Insider Report for CRISPR Therapeutics AG (CRSP)

Signature
/s/ AJ Silver, attorney-in-fact
Issuer symbol
CRSP
Transactions as of
18 Feb 2024
Net transactions value
-$507,498
Form type
4
Filing time
21 Feb 2024, 17:45:17 UTC
Previous filing
16 Feb 2024
Next filing
12 Mar 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRSP Common Shares Options Exercise +13,250 +7.1% 200,627 18 Feb 2024 Direct F1
transaction CRSP Common Shares Sale $507,498 -6,370 -3.2% $79.67 194,257 20 Feb 2024 Direct F2
holding CRSP Common Shares 200,000 18 Feb 2024 The Kulkarni 2023 GRAT

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRSP Restricted Stock Units Options Exercise -13,250 -33% 26,500 18 Feb 2024 Common Shares 13,250 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
F2 Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.
F3 This restricted stock unit award was granted on February 18, 2022 with respect to 53,000 Common Shares, with (i) one quarter of the shares vesting on February 18, 2023, (ii) one quarter of the shares vesting on February 18, 2024, (iii) one quarter of the shares vesting on February 18, 2025, and (iv) one quarter of the shares vesting on February 18, 2026.